MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks Positive Part 3B I
- Product
- DA-1726
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The company’s decision to extend treatment duration from 16 to 24 weeks after preliminary safety/tolerability observations, plus the completion of the last Part 3A patient visit, reduces near-term execution risk and supports continued development planning toward a 48-week Phase 2 study targeted for second-half 2027.
Market read
Traders may view this as a positive pipeline execution milestone that supports the probability of progressing to Phase 2, while awaiting the full Parts 3A and 3B dataset in Q1 2027.
What to watch
The article does not provide new safety signals beyond the extension rationale, and it does not quantify adverse events or durability beyond the stated extension framework.
Background
MetaVia is running a Phase 1 trial for DA-1726, a once-weekly GLP-1R/GCGR dual agonist, with Parts 3A and 3B designed to support Phase 2 readiness in metabolic and alcohol-associated liver disease.
Ticker impact
MetaVia reports last patient completed the Phase 1 Part 3A visit for DA-1726 and extends treatment from 16 to 24 weeks.
Likely upward bias as the market prices improved clinical execution and durability/safety read-through ahead of full Part 3A and 3B data.
The filing is a primary clinical update (last visit completed) plus a stated extension decision driven by preliminary safety/tolerability, alongside previously released Part 3B interim efficacy.
Market effects
Adds incremental momentum to the liver disease GLP-1/GCGR dual-agonist competitive set, potentially influencing sentiment toward early-stage metabolic/liver biotech programs.
Primarily US-listed biotech sentiment via Nasdaq-listed clinical-stage risk appetite.
Limited direct global macro impact; relevant mainly to global investors tracking metabolic and alcohol-associated liver disease pipelines.
Counterpoint
The update is executional (last visit completed) and the key Phase 2 decision hinges on full Part 3A and 3B data, which is still months away.
Key entities
- companyMetaVia Inc.
Nasdaq-listed clinical-stage biotech developing DA-1726 for liver-related cardiometabolic diseases.
- drug_candidateDA-1726
Once-weekly GLP-1R/GCGR dual-receptor agonist being evaluated in Phase 1 Parts 3A and 3B.
- eventPrecision Liver Symposium 2026
Conference where Part 3B interim data were presented.


